Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined with Bevacizumab in Recurrent Glioblastoma
This study is for patients with recurrent Glioblastoma. The purpose of this study is to find out what effects, good and/or bad, the combination of dasatinib and bevacizumab have on this type of cancer. In addition this study aims to find out if there are individual differences and/or tumor characteristics that will affect response to treatment. Dasatinib and bevacizumab are approved for some types of cancer but are not currently approved for use in treating brain cancer. The use of dasatinib and becacizumab in this study is considered investigational.
Back to Clinical Trials list